Serum uric acid as a surrogate marker of favorable response to bevacizumab treatment in patients with metastatic colon cancer

Clinical and Translational Oncology

Volumn 18, Issue 11, 2016, Pages 1082-1087

  Selcukbiricik, F ^a   Kanbay, M ^a   Solak, Y ^b   Bilici, A ^c   Kanitez M ^d   Balik E ^a   Mandel, N M ^a,e  

^a KOÇ UNIVERSITY   (Turkey)

^b Sakarya Education and Research Hospital ^*  (Turkey)

^c ISTANBUL MEDIPOL UNIVERSITY   (Turkey)

^d Department of Neurosurgery   (Turkey)

^e AMERICAN HOSPITAL   (Turkey)

Author keywords

Bevacizumab; Carcinoembryonic antigen; Hypoxia; Metastatic colorectal cancer; Survival; Uric acid

Indexed keywords

BEVACIZUMAB; CA 19-9 ANTIGEN; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; URIC ACID; ANTINEOPLASTIC AGENT; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; COHORT ANALYSIS; COLON CANCER; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; RADIOIMMUNOASSAY; SMOKING; TREATMENT RESPONSE; BLOOD; COLONIC NEOPLASMS; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; BIOMARKERS, TUMOR; COHORT STUDIES; COLONIC NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; URIC ACID;

EID: 84954473135     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-016-1485-1     Document Type: Article

References (20)

1. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335–42.
2. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355(24):2542–50.
3. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357(26):2666–76.
4. Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Archer L, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol. 2010;28(13):2137–43.
5. Kanbay M, Ikizek M, Solak Y, Selcoki Y, Uysal S, Armutcu F, et al. Uric acid and pentraxin-3 levels are independently associated with coronary artery disease risk in patients with stage 2 and 3 kidney disease. Am J Nephrol. 2011;33(4):325–31.
6. Kanbay M, Solak Y, Dogan E, Lanaspa MA, Covic A. Uric acid in hypertension and renal disease: the chicken or the egg? Blood Purif. 2010;30(4):288–95.
7. Gullu H, Erdogan D, Caliskan M, Tok D, Kulaksizoglu S, Yildirir A, et al. Elevated serum uric acid levels impair coronary microvascular function in patients with idiopathic dilated cardiomyopathy. Eur J Heart Fail. 2007;9(5):466–8.
8. Yuan Y, Ikram MK, Jiang S, Lin H, Ren L, Yan H, et al. Hyperuricemia accompanied with changes in the retinal microcirculation in a Chinese high-risk population for diabetes. Biomed Environ Sci. 2011;24(2):146–54.
9. Wijnands JM, Houben AJ, Muris DM, Boonen A, Schram MT, Sep SJ, et al. Uric acid and skin microvascular function: the Maastricht study. J Hypertens. 2015;33(8):1651–7.
10. Matheus AS, Tibiriçá E, da Silva PB, de Fátima Bevilácqua da Matta M, Gomes MB. Uric acid levels are associated with microvascular endothelial dysfunction in patients with type 1 diabetes. Diabet Med. 2011;28(10):1188–93.
11. Kanbay M, Sánchez-Lozada LG, Franco M, Madero M, Solak Y, Rodriguez-Iturbe B, et al. Microvascular disease and its role in the brain and cardiovascular system: a potential role for uric acid as a cardiorenal toxin. Nephrol Dial Transplant. 2011;26(2):430–7.
12. Patschan D, Patschan S, Gobe GG, Chintala S, Goligorsky MS. Uric acid heralds ischemic tissue injury to mobilize endothelial progenitor cells. J Am Soc Nephrol. 2007;18(5):1516–24.
13. Miller WL, Thomas RA, Berne RM, Rubio R. Adenosine production in the ischemic kidney. Circ Res. 1978;43:390–7.
14. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature. 2003;425:516–21.
15. de Andrade DP, Lima JP, Lima AD, Sasse AD, dos Santos LV. Bevacizumab in metastatic colorectal cancer and carcino-embryonic antigen kinetics: case report and review of literature. Anticancer Drugs. 2011;22(Suppl 2):S15–7.
16. Kanbay M, Huddam B, Azak A, Solak Y, Kadioglu GK, Kirbas I, et al. A randomized study of allopurinol on endothelial function and estimated glomular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol. 2011;6(8):1887–94.
17. Maruhashi T, Nakashima A, Soga J, Fujimura N, Idei N, Mikami S, et al. Hyperuricemia is independently associated with endothelial dysfunction in postmenopausal women but not in premenopausal women. BMJ Open. 2013;3(11):e003659.
18. Lanza GA, Crea F. Primary coronary microvascular dysfunction: clinical presentation, pathophysiology, and management. Circulation. 2010;121(21):2317–25.
19. Xia S, Deng SB, Wang Y. Clinical analysis of the risk factors of slow coronary flow. Heart Vessels. 2011;26(5):480–6.
20. Petrelli F, Coinu A, Ghilardi M, Cabiddu M, Zaniboni A, Barni S. Efficacy of oxaliplatin-based chemotherapy + bevacizumab as first-line treatment for advanced colorectal cancer: a systematic review and pooled analysis of published trials. Am J Clin Oncol. 2015;38(2):227–33.